



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



FDA ADVISORY
No. **2019-142**

03 JUN 2019

TO: GENERAL CONSUMING PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Counterfeit Cosmetic Products (Batch 9)

The Food and Drug Administration (FDA) hereby advises the public against the purchase and use of **POND'S PURE WHITE MINERAL CLAY MASK D-TOXX TREATMENT** whose particulars/details are provided below:

PRODUCT DETAILS:

Local Company Name as Reflected on the Label: **Not Indicated**

Address: **Not Indicated**

Country of Manufacture: **Label is in Foreign Language**



FDA, in coordination with the Market Authorization Holder (MAH), Unilever Philippines, Inc., has verified that the aforementioned cosmetic product is **COUNTERFEIT**. According to the MAH, prior to distribution of all imported cosmetic products in the local market, the company revises the product label in compliance to FDA and ASEAN Cosmetic Labeling Requirements.



Counterfeit products, not having gone through the required safety assessment and the verification process of the FDA, pose potential health hazards to the consuming public since their safety and purity cannot be guaranteed. The dangers/hazards may come from ingredients that are not allowed to be part of a cosmetic product or from the contamination of heavy metals such as lead and mercury. The use of substandard and possibly adulterated cosmetic products may result to adverse reactions including but not limited to skin irritation, itchiness, anaphylactic shock and organ failure.


In light of the above, the public is advised to be vigilant against buying and using the aforementioned counterfeit cosmetic product. Moreover, the public is also advised to be vigilant against cosmetic products that might not be duly notified with FDA. Always check if a cosmetic product has been notified with FDA before purchasing it by making use of the embedded *Search* feature of the FDA website accessible at www.fda.gov.ph.

All concerned establishments are warned not to distribute the above-identified violative cosmetic product, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that the product is not sold or made available in their localities or areas of jurisdiction.

To report any suspicious and/or illegal activity involving the said product, the public may contact FDA through its online reporting facility, **eReport**, at www.fda.gov.ph/ereport, or e-mail us at report@fda.gov.ph, or call the Center for Cosmetics Regulation and Research (CCRR) hotline **(02) 857-1900 local 8107/8113**.

Dissemination of the information to all concerned is requested


ROLANDO ENRIQUE D. DOMINGO, MD, DPBO
Undersecretary of Health
Officer-in-Charge, Director General

DTN 20190528094702

